Erenumab and Migraine: Rare Ocular Side Effects Explored
- Mar 12
- 1 min read
Research Summary
A recent case report published in Biologics highlights a rare, late-onset complication associated with erenumab, a medication used for chronic migraine. A 46-year-old woman, who had significant migraine relief from erenumab for over three years, developed symptoms resembling ocular myasthenia gravis, including double vision and drooping eyelids. Although tests were inconclusive for myasthenia gravis, she improved rapidly with pyridostigmine, and her symptoms resolved upon stopping erenumab. Notably, she maintained migraine control without recurring symptoms after re-starting erenumab. This case underscores the importance for clinicians to monitor for delayed, reversible ocular side effects in patients on anti-CGRP therapies.
Study Details
👥 Research Team: Qaqish A, Al Anber A, Abdelhafez G
📚 Published In: Biologics
📅 Publication Date: 2026
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.